<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">grekov</journal-id><journal-title-group><journal-title xml:lang="ru">Вестник хирургии имени И.И. Грекова</journal-title><trans-title-group xml:lang="en"><trans-title>Grekov's Bulletin of Surgery</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">0042-4625</issn><issn pub-type="epub">2686-7370</issn><publisher><publisher-name>Federal State Budgetary Educational Institution of Higher Education «Academician I.P. Pavlov First St. Petersburg State Medical University» of the Ministry of Healthcare of the Russion Federation, FSBEI HE I.P.Pavlov SPbSMU MOH Russia</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.24884/0042-4625-2025-184-4-18-24</article-id><article-id custom-type="elpub" pub-id-type="custom">grekov-2638</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ВОПРОСЫ ОБЩЕЙ И ЧАСТНОЙ ХИРУРГИИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>PROBLEMS OF GENERAL AND SPECIAL SURGERY</subject></subj-group></article-categories><title-group><article-title>Прогностические возможности дооперационной диагностики радиойодрезистентного высокодифференцированного рака щитовидной железы</article-title><trans-title-group xml:lang="en"><trans-title>Prognostic potential of preoperative diagnostics of radioiodine-resistant well-differentiated thyroid cancer</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8918-1730</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ромащенко</surname><given-names>П. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Romashchenko</surname><given-names>P. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ромащенко Павел Николаевич, доктор медицинских наук, профессор, член-корреспондент РАН, начальник кафедры и клиники факультетской хирургии имени С. П. Фёдорова</p><p>194044, Санкт-Петербург, ул. Академика Лебедева, д. 6</p></bio><bio xml:lang="en"><p>Romashchenko Pavel N., Dr. of Sci. (Med.), Professor, Corresponding Member of the RAS, Head of the S. P. Fedorov Department and Clinic of Faculty Surgery</p><p>6, Academica Lebedeva str., Saint Petersburg, 194044</p></bio><email xlink:type="simple">romashchenko@rambler.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1405-7660</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Майстренко</surname><given-names>Н. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Maistrenko</surname><given-names>N. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Майстренко Николай Анатольевич, доктор медицинских наук, профессор, академик РАН, профессор кафедры факультетской хирургии имени С. П. Фёдорова</p><p>194044, Санкт-Петербург, ул. Академика Лебедева, д. 6</p></bio><bio xml:lang="en"><p>Maistrenko Nicolay А., Dr. of Sci. (Med.), Professor, Academician of the RAS, Professor of the S. P. Fedorov Department and Clinic of Faculty Surgery</p><p>6, Academica Lebedeva str., Saint Petersburg, 194044</p></bio><email xlink:type="simple">nik.m.47@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8359-1875</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Симонова</surname><given-names>М. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Simonova</surname><given-names>M. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Симонова Мария Сергеевна, кандидат медицинских наук, врач-хирург кафедры и клиники факультетской хирургии им. С. П. Фёдорова</p><p>194044, Санкт-Петербург, ул. Академика Лебедева, д. 6</p></bio><bio xml:lang="en"><p>Simonova Maria S., Cand. of Sci. (Med.), Surgeon of the S. P. Fedorov Department and Clinic of Faculty Surgery</p><p>6, Academica Lebedeva str., Saint Petersburg, 194044</p></bio><email xlink:type="simple">mariasimonova62@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9499-2164</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Криволапов</surname><given-names>Д. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Krivolapov</surname><given-names>D. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Криволапов Денис Сергеевич, кандидат медицинских наук, преподаватель кафедры факультетской хирургии имени С. П. Фёдорова</p><p>194044, Санкт-Петербург, ул. Академика Лебедева, д. 6</p></bio><bio xml:lang="en"><p>Krivolapov Denis S., Cand. of Sci. (Med.), Teacher of the S. P. Fedorov Department and Clinic of Faculty Surgery</p><p>6, Academica Lebedeva str., Saint Petersburg, 194044</p></bio><email xlink:type="simple">d.s.krivolapov@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Военно-медицинская академия имени С.М. Кирова</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Military Medical Academy</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>22</day><month>10</month><year>2025</year></pub-date><volume>184</volume><issue>4</issue><fpage>18</fpage><lpage>24</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Ромащенко П.Н., Майстренко Н.А., Симонова М.С., Криволапов Д.С., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Ромащенко П.Н., Майстренко Н.А., Симонова М.С., Криволапов Д.С.</copyright-holder><copyright-holder xml:lang="en">Romashchenko P.N., Maistrenko N.A., Simonova M.S., Krivolapov D.S.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.vestnik-grekova.ru/jour/article/view/2638">https://www.vestnik-grekova.ru/jour/article/view/2638</self-uri><abstract><p>Увеличение числа больных высокодифференцированным раком щитовидной железы с нередким выявлением его радиойодрефрактерных форм требует проведения дооперационной диагностики посредством разработки и применения наиболее эффективных высокотехнологичных методов обследования. Наиболее перспективными из них являются молекулярно-генетические исследования пункционного материала. Проанализированы результаты обследования и хирургического лечения 103 больных высокодифференцированным раком щитовидной железы, предоперационное обследование которых было дополнено определением экспрессии натрий-йодидного симпортера и мутации BRAF V600E. Установлены предельное значение NIS, которое позволяет прогнозировать развитие резистентности рака к послеоперационной терапии радиоактивным йодом, а также его взаимосвязь с BRAF-мутацией с целью определения необходимости расширения объема оперативного вмешательства.</p></abstract><trans-abstract xml:lang="en"><p>The increase in the number of patients with well-differentiated thyroid cancer with frequent detection of its radioiodine refractory forms requires preoperative diagnostics through the development and application of the most effective high-tech examination methods, the most promising of which are molecular genetic studies of puncture material. The results of examination and surgical treatment of 103 patients with well-differentiated thyroid cancer were analyzed, the preoperative examination of which was supplemented by determining the expression of the sodium iodide symporter and the BRAF V600E mutation. The limiting value of nIS was established, which allows predicting the development of cancer resistance to postoperative radioactive iodine therapy, as well as its relationship with the BRAF mutation in order to determine the need to expand the scope of surgical intervention.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>высокодифференцированный рак щитовидной железы</kwd><kwd>радиойодрезистентность</kwd><kwd>радиойодтерапия</kwd><kwd>натрий-йодидный симпортер</kwd><kwd>BRAF-мутация</kwd></kwd-group><kwd-group xml:lang="en"><kwd>well-differentiated thyroid cancer</kwd><kwd>radioiodine resistance</kwd><kwd>radioiodine therapy</kwd><kwd>sodium iodide symporter</kwd><kwd>BRAF mutation</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Румянцев П.О., Байдак А.Г. Междисциплинарный банк данных в онкоэндокринологии: радиойодрефрактерный дифференцированный рак щитовидной железы // Digital Diagnostics. – 2022. – Т.3, №1. – С. 86-93. Doi: 10.17816/DD104745.</mixed-citation><mixed-citation xml:lang="en">Rumiantsev P.O., Baidak A.G. Interdisciplinary databank in oncoendocrinology: radioiodine refractory differentiated thyroid cancer. Digital Diagnostics. 2022;3(1):86−93. (In Russ.) Doi: 10.17816/DD104745.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Pacini F., Fuhrer D.., Elisei R. et al. 2022 ETA Consensus Statement: What are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer? Eur Thyroid J. 2022 Jan 1;11(1):e210046. Doi: 10.1530/ETJ-21-0046.</mixed-citation><mixed-citation xml:lang="en">Pacini F., Fuhrer D.., Elisei R. et al. 2022 ETA Consensus Statement: What are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer? Eur Thyroid J. 2022 Jan 1;11(1):e210046. Doi: 10.1530/ETJ-21-0046.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Ромащенко П.Н. Современные подходы к диагностике и хирургическому лечению хромаффинных опухолей: специальность 14.00.27: диссертация на соискание ученой степени доктора медицинских наук / Ромащенко Павел Николаевич, 2007. – 342 с.</mixed-citation><mixed-citation xml:lang="en">Romashchenko P.N. Sovremenny`e podxody` k diagnostike i xirurgicheskomu lecheniyu xromaffinny`x opuxolej: special`nost` 14.00.27: dissertaciya na soiskanie uchenoj stepeni doktora medicinskix nauk / Romashchenko Pavel Nikolaevich, 2007. – 342 s. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Самохвалова Н.А., Майстренко Н.А., Ромащенко П.Н. Программный подход к лечению вторичного гиперпаратиреоза при хронической болезни почек // Вестник хирургии имени И.И. Грекова. – 2013. – Т.172. – №2. – С. 43-46. Doi: 10.24884/0042-4625-2013-172-2-043-046.</mixed-citation><mixed-citation xml:lang="en">Samohvalova N.A., Maystrenko N.A., Romashchenko P.N. Programmed approach to the treatment of secondary hyperparathyroidism in chronic renal disease. Grekov's Bulletin of Surgery. 2013;172(2):043-046. (In Russ.) Doi: 10.24884/0042-4625-2013-172-2-043-046.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Джикия Е.Л., Авилов О.Н., Киселева Я.Ю. и др. Na+/I- симпортер (NIS): структура, функции, экспрессия в норме и опухолях // Вестник Российского научного центра рентгенорадиологии Минздрава России. – 2018. – Т.18, № 1. – С. 1-21.</mixed-citation><mixed-citation xml:lang="en">Dzhikiya E.L., Avilov O.N., Kiseleva Ya.Yu. et al. Sodium/iodide symporter (NIS): structure, function and role in in thyroid diseases. Vestnik Rossijskogo nauchnogo centra rentgenoradiologii Minzdrava Rossii. 2018;18(1):1-21. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Cazarin J., Dupuy C., Pires de Carvalho D. Redox Homeostasis in Thyroid Cancer: Implications in Na+/I- Symporter (NIS) Regulation. Int J Mol Sci. 2022 May 30;23(11):6129. Doi: 10.3390/ijms23116129.</mixed-citation><mixed-citation xml:lang="en">Cazarin J., Dupuy C., Pires de Carvalho D. Redox Homeostasis in Thyroid Cancer: Implications in Na+/I- Symporter (NIS) Regulation. Int J Mol Sci. 2022 May 30;23(11):6129. Doi: 10.3390/ijms23116129.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Ravera S., Reyna-Neyra A., Ferrandino G. et al. The Sodium/Iodide Symporter (NIS): Molecular Physiology and Preclinical and Clinical Applications. Annu Rev Physiol. 2017 Feb 10;79:261-289. Doi: 10.1146/annurev-physiol-022516-034125.</mixed-citation><mixed-citation xml:lang="en">Ravera S., Reyna-Neyra A., Ferrandino G. et al. The Sodium/Iodide Symporter (NIS): Molecular Physiology and Preclinical and Clinical Applications. Annu Rev Physiol. 2017 Feb 10;79:261-289. Doi: 10.1146/annurev-physiol-022516-034125.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Tavares C., Coelho M.J., Eloy C. et al. NIS expression in thyroid tumors, relation with prognosis clinicopathological and molecular features. Endocr Connect. 2018 Jan;7(1):78-90. Doi: 10.1530/EC-17-0302.</mixed-citation><mixed-citation xml:lang="en">Tavares C., Coelho M.J., Eloy C. et al. NIS expression in thyroid tumors, relation with prognosis clinicopathological and molecular features. Endocr Connect. 2018 Jan;7(1):78-90. Doi: 10.1530/EC-17-0302.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Dong H., Shen W.Z., Yan Y.J. et al. Effects of BRAF(V600E) mutation on Na(+)/I(-) symporter expression in papillary thyroid carcinoma. J Huazhong Univ Sci Technolog Med Sci. 2016 Feb;36(1):77-81. Doi: 10.1007/s11596-016-1545-3.</mixed-citation><mixed-citation xml:lang="en">Dong H., Shen W.Z., Yan Y.J. et al. Effects of BRAF(V600E) mutation on Na(+)/I(-) symporter expression in papillary thyroid carcinoma. J Huazhong Univ Sci Technolog Med Sci. 2016 Feb;36(1):77-81. Doi: 10.1007/s11596-016-1545-3.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Liu J., Liu Y., Lin Y., Liang J. Radioactive Iodine-Refractory Differentiated Thyroid Cancer and Redifferentiation Therapy. Endocrinol Metab (Seoul). 2019 Sep;34(3):215-225. Doi: 10.3803/EnM.2019.34.3.215.</mixed-citation><mixed-citation xml:lang="en">Liu J., Liu Y., Lin Y., Liang J. Radioactive Iodine-Refractory Differentiated Thyroid Cancer and Redifferentiation Therapy. Endocrinol Metab (Seoul). 2019 Sep;34(3):215-225. Doi: 10.3803/EnM.2019.34.3.215.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Haugen B.R., Alexander E.K., Bible K.C. et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016 Jan;26(1):1-133. Doi: 10.1089/thy.2015.0020.</mixed-citation><mixed-citation xml:lang="en">Haugen B.R., Alexander E.K., Bible K.C. et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016 Jan;26(1):1-133. Doi: 10.1089/thy.2015.0020.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Paschke R., Cantara S., Crescenzi A. et al. Sobrinho Simoes M. European Thyroid Association Guidelines regarding Thyroid Nodule Molecular Fine-Needle Aspiration Cytology Diagnostics. Eur Thyroid J. 2017 Jul;6(3):115-129. Doi: 10.1159/000468519.</mixed-citation><mixed-citation xml:lang="en">Paschke R., Cantara S., Crescenzi A. et al. Sobrinho Simoes M. European Thyroid Association Guidelines regarding Thyroid Nodule Molecular Fine-Needle Aspiration Cytology Diagnostics. Eur Thyroid J. 2017 Jul;6(3):115-129. Doi: 10.1159/000468519.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Scheffel R.S., Dora J.M., Maia A.L. BRAF mutations in thyroid cancer. Curr Opin Oncol. 2022 Jan 1;34(1):9-18. Doi: 10.1097/CCO.0000000000000797.</mixed-citation><mixed-citation xml:lang="en">Scheffel R.S., Dora J.M., Maia A.L. BRAF mutations in thyroid cancer. Curr Opin Oncol. 2022 Jan 1;34(1):9-18. Doi: 10.1097/CCO.0000000000000797.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Борискова М.Е., Фарафонова У.В., Панкова П.А. и др. Оптимизация хирургической тактики лечения BRAF-положительного папиллярного рака щитовидной железы // Клиническая и экспериментальная тиреоидология. – 2018. – Т. 14, № 1. – С. 25-33. Doi: 10.14341/ket9424.</mixed-citation><mixed-citation xml:lang="en">Boriskova M.E., Farafonova U.V., Pankova P.A. et al. Surgical tactics optimization for treatment of BRAF positive papillary thyroid cancer. Clinical and experimental thyroidology. 2018;14(1):25-33. (In Russ.) Doi: 10.14341/ket9424</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Румянцев П.О., Бородавина Е.В., Кутукова С.И., Васильева Е. В. Персонализированная терапия ленватинибом прогрессирующего радиойодрефрактерного дифференцированного рака щитовидной железы в реальной клинической практике. Опухоли головы и шеи. –2021. –</mixed-citation><mixed-citation xml:lang="en">Rumyantsev P.O., Borodavina E.V., Kutukova S.I., Vasilyeva E.B. Personalized therapy with lenvatinib for progressive radioiodine refractory differentiated thyroid cancer in routine clinical practice. Head and Neck Tumors (HNT). 2021;11(3):47-55. (In Russ.) Doi: 10.17650/2222-1468-2021-11-3-47-55.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Т. 11, № 3. – С. 47-55. Doi: 10.17650/2222-1468-2021-11-3-47-55.</mixed-citation><mixed-citation xml:lang="en">Oh J.M., Ahn B.C. Molecular mechanisms of radioactive iodine refractoriness in differentiated thyroid cancer: Impaired sodium iodide symporter (NIS) expression owing to altered signaling pathway activity and intracellular localization of NIS. Theranostics. 2021 Apr 15;11(13):6251-6277. Doi: 10.7150/thno.57689.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Oh J.M., Ahn B.C. Molecular mechanisms of radioactive iodine refractoriness in differentiated thyroid cancer: Impaired sodium iodide symporter (NIS) expression owing to altered signaling pathway activity and intracellular localization of NIS. Theranostics. 2021 Apr 15;11(13):6251-6277. Doi: 10.7150/thno.57689.</mixed-citation><mixed-citation xml:lang="en">Sui X., Sui Y., Wang Y. LARP7 in papillary thyroid carcinoma induces NIS expression through suppression of the SHH signaling pathway. Mol Med Rep. 2018 Jun;17(6):7521-7528. Doi: 10.3892/mmr.2018.8856.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Sui X., Sui Y., Wang Y. LARP7 in papillary thyroid carcinoma induces NIS expression through suppression of the SHH signaling pathway. Mol Med Rep. 2018 Jun;17(6):7521-7528. Doi: 10.3892/mmr.2018.8856.</mixed-citation><mixed-citation xml:lang="en">Tchekmedyian V., Dunn L., Sherman E. et al. Enhancing Radioiodine Incorporation in BRAF-Mutant, Radioiodine-Refractory Thyroid Cancers with Vemurafenib and the Anti-ErbB3 Monoclonal Antibody CDX-3379: Results of a Pilot Clinical Trial. Thyroid. 2022 Mar;32(3):273-282. Doi: 10.1089/thy.2021.0565.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Tchekmedyian V., Dunn L., Sherman E. et al. Enhancing Radioiodine Incorporation in BRAF-Mutant, Radioiodine-Refractory Thyroid Cancers with Vemurafenib and the Anti-ErbB3 Monoclonal Antibody CDX-3379: Results of a Pilot Clinical Trial. Thyroid. 2022 Mar;32(3):273-282. Doi: 10.1089/thy.2021.0565.</mixed-citation><mixed-citation xml:lang="en">Zhang H., Chen D. Synergistic inhibition of MEK/ERK and BRAF V600E with PD98059 and PLX4032 induces sodium/iodide symporter (NIS) expression and radioiodine uptake in BRAF mutated papillary thyroid cancer cells. Thyroid Res. 2018 Oct 11;11:13. Doi: 10.1186/s13044-018-0057-6.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang H., Chen D. Synergistic inhibition of MEK/ERK and BRAF V600E with PD98059 and PLX4032 induces sodium/iodide symporter (NIS) expression and radioiodine uptake in BRAF mutated papillary thyroid cancer cells. Thyroid Res. 2018 Oct 11;11:13. Doi: 10.1186/s13044-018-0057-6.</mixed-citation><mixed-citation xml:lang="en">Wächter S., Wunderlich A., Greene B.H. et al. Selumetinib Activity in Thyroid Cancer Cells: Modulation of Sodium Iodide Symporter and Associated miRNAs. Int J Mol Sci. 2018 Jul 17;19(7):2077. Doi: 10.3390/ijms19072077.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Wächter S., Wunderlich A., Greene B.H. et al. Selumetinib Activity in Thyroid Cancer Cells: Modulation of Sodium Iodide Symporter and Associated miRNAs. Int J Mol Sci. 2018 Jul 17;19(7):2077. Doi: 10.3390/ijms19072077.</mixed-citation><mixed-citation xml:lang="en">Lu J., Zhang J., Wang M. et al. A meta-analysis of the efficacy and toxicity of tyrosine kinase inhibitors in treating patients with different types of thyroid cancer: how to choose drugs appropriately? Curr Opin Oncol. 2023 Mar 1;35(2):132-144. Doi: 10.1097/CCO.0000000000000924.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Lu J., Zhang J., Wang M. et al. A meta-analysis of the efficacy and toxicity of tyrosine kinase inhibitors in treating patients with different types of thyroid cancer: how to choose drugs appropriately? Curr Opin Oncol. 2023 Mar 1;35(2):132-144. Doi: 10.1097/CCO.0000000000000924.</mixed-citation><mixed-citation xml:lang="en">Romashchenko P.N., Krivolapov D.S., Simonova M.S. Significance of preoperative determination of the expression of sodium-iodide symporter in the selection of volume surgical intervention and forecast the efficiency of radioiodine therapy in patients with highly differentiated thyroid cancer. Sciences of Europe. 2021;67-2(67):62-67. (In Russ.) Doi: 10.24412/3162-2364-2021-67-2-62-67.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Ромащенко П.Н., Криволапов Д.С., Симонова М.С. Значимость дооперационного определения экспрессии натрий-йодидного симпортера в выборе объема оперативного вмешательства и прогнозе эффективности радиойодтерапии у больных высокодифференцированным раком щитовидной железы // Sciences of Europe. – 2021. – № 67-2(67). – С. 62-67. Doi: 10.24412/3162-2364-2021-67-2-62-67.</mixed-citation><mixed-citation xml:lang="en">Romashchenko P.N., Maistrenko N.A., Krivolapov D.S., Simonova M.S. Molecular-genetic testing in thyroid surgery. Tavricheskij mediko-biologicheskij vestnik. 2021;24(2):118-126. (In Russ.) Doi:10.37279/2070-8092-2021-24-2-118-126.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Ромащенко П.Н., Майстренко Н.А., Криволапов Д.С., Симонова М.С. Молекулярно-генетические исследования в хирургии щитовидной железы // Таврический медико-биологический вестник. – 2021. – Т. 24, № 2. – С. 118-126. Doi:10.37279/2070-8092-2021-24-2-118-126.</mixed-citation><mixed-citation xml:lang="en">Mudunov A.M., Rumiantsev P.O., Podvyaznikov S.O. et al. Rezolyuciya po itogam E`kspertnogo soveta «Sovremenny`e podxody` k lecheniyu differencirovannogo raka shhitovidnoj zhelezy`, rezistentnogo k terapii radioaktivny`m jodom. Head and Neck Tumors (HNT). 2015; 5 (3): 59-63. (In  Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Мудунов А.М., Румянцев П.О., Подвязников С.О. и др. Резолюция по итогам Экспертного совета «Современные подходы к лечению дифференцированного рака щитовидной железы, резистентного к терапии радиоактивным йодом. – Опухоли головы и шеи. – 2015. – T. 5, № 3. – С. 59-63.</mixed-citation><mixed-citation xml:lang="en">Rumyantsev P.O., Fomin D.K., Rumyantseva U.V. Criteria of well-differentiated thyroid carcinoma resistance to radioiodine therapy. Head and Neck Tumors (HNT). 2014;(3):4-9. (In Russ.) Doi: 10.17650/2222-1468-2014-0-3-4-9.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Румянцев П.О., Фомин Д.К., Румянцева У.В. Критерии резистентности высокодифференцированного рака щитовидной железы к терапии радиоактивным йодом. –Опухоли головы и шеи. – 2014. – № 3. – С. 4-9. Doi: 10.17650/2222-1468-2014-0-3-4-9.</mixed-citation><mixed-citation xml:lang="en">Romashchenko P.N. Obosnovanie dostupov pri e`ndovideoxirurgicheskix vmeshatel`stvax na nadpochechnikax (kliniko-anatomicheskoe issledovanie): special`nost` 14.01.17: dissertaciya na soiskanie uchenoj stepeni kandidata medicinskix nauk / Romashchenko Pavel Nikolaevich, 2000. – 161 s. (In Russ)</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Ромащенко П.Н. Обоснование доступов при эндовидеохирургических вмешательствах на надпочечниках (клинико-анатомическое исследование): специальность 14.01.17: диссертация на соискание ученой степени кандидата медицинских наук / Ромащенко Павел Николаевич, 2000. – 161 с.</mixed-citation><mixed-citation xml:lang="en">Ромащенко П.Н. Обоснование доступов при эндовидеохирургических вмешательствах на надпочечниках (клинико-анатомическое исследование): специальность 14.01.17: диссертация на соискание ученой степени кандидата медицинских наук / Ромащенко Павел Николаевич, 2000. – 161 с.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
